NCT07136116View on ClinicalTrials.gov

Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 28, 2030

Study Completion Date

February 28, 2030

Conditions
Ulcerative Colitis
Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY